Abstract: The invention is in the field of immunology and vaccinology. In particular, it relates to antigens derived from Chlamydia trachomatis that are expressed on the cell surface and so are ideal for use in immunisation as well as combinations of these antigens.

Abstract: The invention relates to compositions comprising combinations of Chlamydia trachomatis antigens and their use in vaccines. Specific combinations may be selected from a first antigen group of PepA, LcrE, ArtJ, DnaK, and CT398, and a second antigen group of PepA, LcrE, ArtJ, DnaK, CT398, OmpH-like, L7/L12, OmcA, AtoS, CT547, Eno, HtrA and MurG. The invention further relates to the use of combinations of adjuvants for use with antigens associated with a sexually transmissible disease, such as Chlamydia trachomatis antigens. Preferred adjuvant combinations include mineral salts, such as aluminium salts and oligonucleotides comprising a CpG motif.

Abstract: Proteins encoded by Chlamydia trachomatis which are immunogenic in humans as a consequence of infection have been identified using Western blots of two-dimensional electrophoretic maps. Several known immunogens were identified, as were proteins not previously known to be immunogens, and proteins not previously reported as expressed gene products.

Abstract: The published genomic sequence of Chlamydia pneumoniae reveals over 1000 putative encoded proteins but does not itself indicate which of these might be useful antigens for immunization and vaccination or for diagnosis. This difficulty is addressed by the invention, which provides a number of C. pneumoniae protein sequences suitable for vaccine production and development and/or for diagnostic purposes.

Abstract: The invention provides methods of obtaining immunogenic proteins from genomic sequences including Neisseria, including the amino acid sequences and the corresponding nucleotide sequences, as well as the genomic sequence of Neisseria meningitidis B. The proteins so obtained are useful antigens for vaccines, immunogenic compositions, and/or diagnostics.

Abstract: The invention provides proteins from Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.

Abstract: The invention provides proteins from Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.

Abstract: Uses of the plasmid-encoded protein pgp3 from C. trachomatis, serotype D, purified by ion exchange column chromatography and shown to be suitable for quantitative immunoassay on clinical samples in an ELISA format, in methods of eliciting and diagnosing an immune response are described.

Abstract: The present invention provides antigenic proteins of Chlamydia trachomatis. The proteins of the present invention are useful for eliciting an immune response to Chlamydia in a patient. For example, an effective amount of protein of the present invention or fraction thereof may be administered to a patient for eliciting a Chlamydia specific immune response. In another example, a method of raising an antibody specific for Chlamydia trachomatis elementary bodies (EB) is provided in which a protein of the present invention is administered to a patient.

Abstract: The present invention provides antigenic proteins of Chlamydia trachomatis. The proteins of the present invention are useful for eliciting an immune response to Chlamydia in a patient. For example, an effective amount of protein of the present invention or fraction thereof may be administered to a patient for eliciting a Chlamydia specific immune response. In another example, a method of raising an antibody specific for Chlamydia trchomatis elementary bodies (EB) is provided in which a protein of the present invention is administered to a patient.

Abstract: The invention provides methods of obtaining immunogenic proteins from genomic sequences including Neisseria, including the amino acid sequences and the corresponding nucleotide sequences, as well as the genomic sequence of Neisseria meningitidis B.

Abstract: The present invention provides antigenic proteins of Chlamydia trachomatis. The proteins of the present invention are useful for eliciting an immune response to Chlamydia in a patient. For example, an effective amount of protein of the present invention or fraction thereof may be administered to a patient for eliciting a Chlamydia specific immune response. In another example, a method of raising an antibody specific for Chlamydia trchomatis elementary bodies (EB) is provided in which a protein of the present invention is administered to a patient.

Abstract: The present invention relates to antigenic proteins from Chlamydia trachomatis. A method for inducing an immune response with an immunogenic Chlamydia protein is provided in which an effective amount of an immunogenic Chlamydia protein is administered to a subject. In one example, the immunogenic Chlamydia protein has a molecular weight of about 15.8 kDa and a pI of about 4.8. In another example, the immunogenic Chlamydia protein has an N-terminal amino acid sequence of TTESLETLVE (SEQ ID NO: 2). In another example, the immunogenic Chlamydia protein is Chlamydia ribosomal protein L7/L12 or a serovar homologue of Chlamydia ribosomal protein L7/L12.

Abstract: A new recombinant form of the plasmid-encoded protein pgp3 from C. trachomatis, serotype D, was purified by ion exchange column chromatography and shown to be suitable for quantitative immunoassay on clinical samples in an ELISA format.

Abstract: A new recombinant form of the plasmid-encoded protein pgp3 from C. trachomatis, serotype D, was purified by ion exchange column chromatography and shown to be suitable for quantitative immunoassy on clinical samples in an ELISA format.

Abstract: The invention provides methods of obtaining immunogenic proteins from genomic sequences including Neisseria, including the amino acid sequences and the corresponding nucleotide sequences, as well as the genomic sequence of Neisseria meningitidis B. The proteins so obtained are useful antigens for vaccines, immunogenic compositions, and/or diagnostics.

Abstract: The published genomic sequence of Chlamydia trachomatis reveals over 1000 putative encoded proteins but does not itself indicate which of these might be useful antigens for immunisation and vaccination or for diagnosis. This difficulty is addressed by the invention, which provides a number of C.trachomatis protein sequences suitable for vaccine production and development and/or for diagnosis purposes.

Abstract: A new recombinant form of the plasmid-encoded protein pgp3 from C. trachomatis, serotype D, was purified by ion exchange column chromatography and shown to be suitable for quantitative immunoassy on clinical samples in an BLISA format.

Abstract: A new recombinant form of the plasmid-encoded protein pgp3 from C. trachomatis, serotype D, to be used in immunogenic compositions and in the preparation of immunogenic compositions was purified by ion exchange column chromatography and shown to be suitable for quantitative immunoassy on clinical samples in an ELISA format.

Abstract: A plasmid isolated from Clamydia trachomatis is described, which comprises 8 genes encoding proteins useful in the formulation of vaccines or diagnostic test for determining the bacterium or specific antibodies generated during C. trachomatis infections; in particular the recombinant fusion MS2-pgp3D protein is described comprising polypeptidic sequences encoded by pCT and immunogenic in the course of infections in man. A method for preparing said protein in E. coli further described.